Urinary Tract Infection Treatment Market to Grow at a CAGR of 3.2% to reach US$ 11,614.32 million from 2020 to 2027

Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Penicillin and Combinations, Quinolones, Cephalosporin, Aminoglycoside Antibiotics, Sulphonamides, Nutritional Supplements), Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection), Distribution Channel (Hospital Pharmacies, Gynecology and Urology Clinics, Retail Pharmacies and Drug Stores, Online Drug Stores), and Geography

Publication Month: Nov 2020 | Report Code: TIPRE00005931 | No. of Pages: No. of Pages241 | Category: Pharmaceuticals | Status: Published

The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027.

The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the Urinary Tract Infection Treatment market to a certain extent.

Lucrative Regional Markets for Urinary Tract Infection Treatment



Lucrative Regional Markets for Urinary Tract Infection Treatment

Get more information on this report :


Market Insights


Growing Incidence of Urinary Tract Infections

Women are at a higher risk of developing urinary tract infections (UTIs) than men. UTIs, if go untreated, can lead to severe pain along with serious consequences to kidneys. UTIs show certain symptoms such as persistent urge to urinate, inflammation, change in appearance of urine, and nausea. The increasing prevalence of UTIs is one of the prominent factors driving the growth of the urinary tract infection treatment market. For instance, according to a study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020, UTIs accounts for ~6 million physicians visits each year in the US.

Certain risk factors such as sexual activity, poor hygiene, and aging may cause UTIs. Increasing incidence of these risk factors are also estimated to drive the urinary tract infection treatment market growth by 2027. According to a study published in the International Journal of Environmental Research and Public Health in 2019, patients with existing chronic conditions such as coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes mellitus (DM) have high possibilities of acquiring UTIs. Therefore, the high epidemiology of UTI generates demand for its treatment products, eventually driving the market growth.

Drug Class-Based Insights

Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment..

Urinary Tract Infection Treatment Market, by Drug Class – 2019 and 2027



Urinary Tract Infection Treatment Market, by Drug Class – 2019 and 2027

Get more information on this report :


Indication-Based Insights

The urinary tract infection treatment market, by indication, is segmented into complicated urinary tract infections and uncomplicated urinary tract infections. The complicated urinary tract infections segment held a larger market share in 2019; also, the segment is anticipated to register a higher CAGR in the market during the forecast period.

Distribution Channel-Based Insights

The urinary tract infection treatment market, by distribution channel, is segmented into hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores. The hospital pharmacies distribution channel segment held the largest share of the market in 2019, whereas online drug stores segment is anticipated to register the highest CAGR in the market during the forecast period.

Strategic Insights

Report CoverageDetails
Market Size Value inUS$ 9,106.40 Million in 2019
Market Size Value byUS$ 11,614.32 Million by 2027
Growth rateCAGR of 3.2% from 2020-2027
Forecast Period2020-2027
Base Year2020
No. of Pages241
No. of Tables165
No. of Charts & Figures88
Historical data availableYes
Segments coveredDrug Class , Indication , Distribution Channel , and Geography
Regional scopeNorth America; Europe; Asia Pacific; Latin America; MEA
Country scopeUS, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The urinary tract infection treatment market players—such as Shionogi & Co., Ltd.; Teva Pharmaceutical Industries Ltd;  Allergan; and Pfizer—have been adopting several organic and inorganic strategies to enhance their revenue and market standings. For instance, in April 2019, Teva Pharmaceutical Industries Ltd announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the US.

Urinary Tract Infection Treatment Market– by Drug Class

  • Penicillin and Combinations
  • Quinolones
  • Cephalosporin
  • Aminoglycoside Antibiotics
  • Sulphonamides
  • Nutritional Supplements


Urinary Tract Infection Treatment Market– by Indication

  • Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection


Urinary Tract Infection Treatment Market– by Distribution Channel

  • Hospital Pharmacies
  • Gynaecology and Urology Clinics
  • Retail Pharmacies and Drug Store
  • Online Drug Stores


Urinary Tract Infection Treatment Market – by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of Middle East &Africa
  • South and Central America
    • Brazil
    • Argentina
    • Rest of South and Central America

Company Profiles

  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V.
  • ALLERGAN
  • Pfizer Inc.
  • Cipla Ltd
  • F. Hoffmann-La Roche Ltd
  • Shionogi Inc.
  • Amway
  • DuPont Nutrition & Biosciences

The List of Companies - Urinary Tract Infection Treatment Market

 

  1. Teva Pharmaceutical Industries Ltd
  2. Sun Pharmaceutical Industries Ltd
  3. Mylan N.V.
  4. ALLERGAN
  5. Pfizer Inc.
  6. Cipla Ltd
  7. F. Hoffmann-La Roche Ltd
  8. Shionogi Inc.
  9. Amway
  10. DuPont Nutrition & Biosciences
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the urinary tract infection treatment market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global urinary tract infection treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00005931
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak To Analyst
Pricing
  • $3000
  • $4550 $3640
  • $6550 $5240
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount